問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Digestive System Department

Division of General Internal Medicine

Division of General Surgery

Division of Radiation Therapy

Division of Hematology & Oncology

更新時間：2023-09-19

趙毅Chao, Yee
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 11 個月

Recruiting Trial

65Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

趙毅

List

194Cases

2009-05-01 - 2011-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2009-08-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2009-11-30 - 2011-11-29

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2006-12-31 - 2009-01-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2011-09-30 - 2014-12-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-10-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2018-10-01 - 2021-08-31

Phase II

A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

  • Condition/Disease

    Advanced Pancreatic Cancer

  • Test Drug

    Cabiralizumab (BMS-986227, FPA008)

Participate Sites
2Sites

Terminated2Sites

李重賓
Taipei Veterans General Hospital

Digestive System Department

2012-03-01 - 2014-11-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2014-11-01 - 2019-03-31

Phase III

ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients with Unresectable Advanced or Recurrent Gastric Cancer

  • Condition/Disease

    Unresectable Advanced or Recurrent Gastric Cancer

  • Test Drug

    ONO-4538

Participate Sites
9Sites

Terminated9Sites

2013-10-01 - 2020-07-31

Phase III

A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

  • Condition/Disease

    Locally Advanced or Metastatic Pancreatic Cancer

  • Test Drug

    NC-6004

Participate Sites
17Sites

Terminated17Sites

蘇五洲
National Taiwan University Hospital

Division of Hematology & Oncology

1 16 17 18 19 20
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB